Form 4: PDS Biotechnology Director Acquires 9,000 Stock Options
SEC Form 4 Filing
Gregory Gene Freitag, a director of PDS Biotechnology Corp, acquired 9,000 employee stock options on June 24, 2024.
Summary
- Gregory Gene Freitag, a director of PDS Biotechnology Corporation, filed a Form 4 on June 25, 2024.
- The filing reports a transaction that occurred on June 24, 2024, where Freitag acquired 9,000 employee stock options with an exercise price of $2.86.
- These options vest fully on the first anniversary of the grant date, contingent upon Freitag's continued service as a director.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it is a standard regulatory filing reporting the acquisition of stock options by a director.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as directors and officers. This allows the public to see if company insiders are buying or selling company stock.
Stakeholder Impact
- The acquisition of stock options by a director could be viewed positively by shareholders as it aligns the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/24/2024 | Date of transaction: Director acquired 9,000 employee stock options. |
| 06/24/2024 | Grant date of the stock options. |
| 06/24/2034 | Expiration date of the stock options. |
| 06/25/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.